JP6489556B2 - マルチコンパートメント脂質ナノ粒子 - Google Patents

マルチコンパートメント脂質ナノ粒子 Download PDF

Info

Publication number
JP6489556B2
JP6489556B2 JP2016528592A JP2016528592A JP6489556B2 JP 6489556 B2 JP6489556 B2 JP 6489556B2 JP 2016528592 A JP2016528592 A JP 2016528592A JP 2016528592 A JP2016528592 A JP 2016528592A JP 6489556 B2 JP6489556 B2 JP 6489556B2
Authority
JP
Japan
Prior art keywords
lipid
compartment
nanoparticles
hydrophilic
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016528592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525143A (ja
JP2016525143A5 (enExample
Inventor
フェーヴル，ヴィンセント
ルシュール，シルヴィアンヌ
オリヴォン，ミシェル
ワッタラ，モディボ
コン，チー チュオン
コン，チー チュオン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Sud filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2016525143A publication Critical patent/JP2016525143A/ja
Publication of JP2016525143A5 publication Critical patent/JP2016525143A5/ja
Application granted granted Critical
Publication of JP6489556B2 publication Critical patent/JP6489556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
JP2016528592A 2013-07-25 2014-07-24 マルチコンパートメント脂質ナノ粒子 Active JP6489556B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1357363 2013-07-25
FR1357363A FR3008900B1 (fr) 2013-07-25 2013-07-25 Nanoparticules lipidiques multicompartimentees
PCT/FR2014/051922 WO2015011419A1 (fr) 2013-07-25 2014-07-24 Nanoparticules lipidiques multicompartimentées

Publications (3)

Publication Number Publication Date
JP2016525143A JP2016525143A (ja) 2016-08-22
JP2016525143A5 JP2016525143A5 (enExample) 2017-08-10
JP6489556B2 true JP6489556B2 (ja) 2019-03-27

Family

ID=49378477

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016528592A Active JP6489556B2 (ja) 2013-07-25 2014-07-24 マルチコンパートメント脂質ナノ粒子

Country Status (7)

Country Link
US (1) US9757337B2 (enExample)
EP (1) EP3024566B1 (enExample)
JP (1) JP6489556B2 (enExample)
CN (1) CN105408015B (enExample)
CA (1) CA2914551C (enExample)
FR (1) FR3008900B1 (enExample)
WO (1) WO2015011419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017183635A (ja) * 2016-03-31 2017-10-05 ソニー株式会社 半導体装置、半導体装置の製造方法、集積基板、及び、電子機器
WO2020223813A1 (en) * 2019-05-07 2020-11-12 University Health Network Nanoemulsion with porphyrin shell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06183953A (ja) * 1991-06-24 1994-07-05 Nippon Oil & Fats Co Ltd 混合脂質膜小胞
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
WO1995013796A1 (en) * 1993-11-16 1995-05-26 Depotech Corporation Vesicles with controlled release of actives
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
ATE514676T1 (de) * 1999-11-24 2011-07-15 Sugen Inc Ionisierbare indolinon derivate und deren verwendung als ptk liganden
FR2805761B1 (fr) 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
FR2857263B1 (fr) * 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
ES2617063T3 (es) * 2007-03-30 2017-06-15 Xisle Pharma Ventures Trust Composición de vesículas lipídicas bifásicas y método para tratar la displasia de cuello uterino por suministro intravaginal
EP2172263A4 (en) * 2007-07-02 2015-08-05 Nisshin Oillio Group Ltd E / H / E EMULSION COMPOSITION
EP2039352A1 (en) * 2007-09-18 2009-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules
CN100558459C (zh) * 2007-12-14 2009-11-11 天津理工大学 以脂质体作为微聚合器制备聚合物微球
CN101366697A (zh) * 2008-08-14 2009-02-18 沈阳万爱普利德医药科技有限公司 一种新的包含紫杉醇类物质的注射用纳米脂质载体及其制备方法

Also Published As

Publication number Publication date
US20160158153A1 (en) 2016-06-09
JP2016525143A (ja) 2016-08-22
WO2015011419A1 (fr) 2015-01-29
CN105408015A (zh) 2016-03-16
FR3008900A1 (fr) 2015-01-30
EP3024566A1 (fr) 2016-06-01
US9757337B2 (en) 2017-09-12
CA2914551A1 (fr) 2015-01-29
FR3008900B1 (fr) 2018-03-30
EP3024566B1 (fr) 2019-05-01
CN105408015B (zh) 2019-03-12
CA2914551C (fr) 2021-05-04

Similar Documents

Publication Publication Date Title
Laouini et al. Preparation, characterization and applications of liposomes: state of the art
Kumar et al. Self-nanoemulsifying drug delivery system of fisetin: Formulation, optimization, characterization and cytotoxicity assessment
Takahashi et al. Efficient preparation of liposomes encapsulating food materials using lecithins by a mechanochemical method
Mehandole et al. Core–shell type lipidic and polymeric nanocapsules: the transformative multifaceted delivery systems
Zhu et al. Galangin-loaded, liver targeting liposomes: Optimization and hepatoprotective efficacy
AU2002312777A1 (en) Method and composition for solubilising a biologically active compound with low water solubility
JP2002507966A (ja) 薬学的組成物の調製
WO2002080883A2 (en) Method and composition for solubilising a biologically active compound with low water solubility
Kumar et al. Novel approaches for enhancement of drug bioavailability
Devalapally et al. Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs
WO2020203961A1 (ja) 脂質膜構造体及びその製造方法
Wang et al. A modified thin film method for large scale production of dimeric artesunate phospholipid liposomes and comparison with conventional approaches
Nayak et al. Unlocking the potential of bilosomes and modified bilosomes: a comprehensive journey into advanced drug delivery trends
JP5494054B2 (ja) 二段階乳化によるリポソーム製造方法
Jash et al. Heat-stable liposomes from milk fat globule membrane phospholipids for pH-triggered delivery of hydrophilic and lipophilic bioactives
Joseph et al. Solid lipid nanoparticles for drug delivery
Gopi et al. Liposomal nanostructures: Properties and applications
JP6489556B2 (ja) マルチコンパートメント脂質ナノ粒子
Tawani et al. Niosomes: A promising nanocarrier approach for drug delivery
Tamayo-Esquivel et al. Evaluation of the enhanced oral effect of omapatrilat-monolein nanoparticles prepared by the emulsification-diffusion method
Zolkepli et al. Harnessing Brucea Javanica: Development and characterization of lipid-based niosomes for diabetes treatment
Patel et al. Lipid-based drug delivery system: spotlight on nanoemulsion as versatile nanocarrier
JP2016525143A5 (enExample)
Saha et al. Fabrication and in-vitro evaluation of liposomal quercetin and its optimization
Pylypenko et al. Nanobiotechnological obtaining of liposomal forms of antioxidant preparations based on bioflavonoids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190219

R150 Certificate of patent or registration of utility model

Ref document number: 6489556

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250